Does the media refer more to LIVN or BAX?

In the previous week, Baxter International had 8 more articles in the media than LivaNova. MarketBeat recorded 21 mentions for Baxter International and 13 mentions for LivaNova. Baxter International's average media sentiment score of 1.02 beat LivaNova's score of 0.68 indicating that Baxter International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Baxter International 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PEN or LIVN?

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 8.95 $177.69M $4.07 78.36 LivaNova $1.39B 3.16 -$242.47M $3.38 23.55

Is PEN or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Penumbra's net margin of 10.67%. LivaNova's return on equity of 16.35% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% LivaNova 12.82% 16.35% 7.76%

Does the media prefer PEN or LIVN?

In the previous week, LivaNova had 6 more articles in the media than Penumbra. MarketBeat recorded 13 mentions for LivaNova and 7 mentions for Penumbra. Penumbra's average media sentiment score of 1.09 beat LivaNova's score of 0.68 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, SNN or LIVN?

Smith & Nephew SNATS has higher revenue and earnings than LivaNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.30B 1.87 $625M N/A N/A LivaNova $1.39B 3.16 -$242.47M $3.38 23.55

Does the media prefer SNN or LIVN?

In the previous week, LivaNova had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 13 mentions for LivaNova and 9 mentions for Smith & Nephew SNATS. LivaNova's average media sentiment score of 0.68 beat Smith & Nephew SNATS's score of 0.39 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, GMED or LIVN?

Globus Medical has higher revenue and earnings than LivaNova. Globus Medical is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.40 $537.87M $3.91 19.05 LivaNova $1.39B 3.16 -$242.47M $3.38 23.55

Is GMED or LIVN more profitable?

Globus Medical has a net margin of 17.02% compared to LivaNova's net margin of 12.82%. LivaNova's return on equity of 16.35% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 17.02% 14.57% 12.62% LivaNova 12.82% 16.35% 7.76%

Does the media prefer GMED or LIVN?

In the previous week, LivaNova had 8 more articles in the media than Globus Medical. MarketBeat recorded 13 mentions for LivaNova and 5 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.87 beat LivaNova's score of 0.68 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, LIVN or GKOS?

Glaukos has lower revenue, but higher earnings than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.16 -$242.47M $3.38 23.55 Glaukos $507.44M 19.77 -$187.69M -$3.25 N/A

Is LIVN or GKOS more profitable?

LivaNova has a net margin of 12.82% compared to Glaukos' net margin of -30.68%. LivaNova's return on equity of 16.35% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% Glaukos -30.68% -6.37% -4.78%

Does the media prefer LIVN or GKOS?

In the previous week, LivaNova had 8 more articles in the media than Glaukos. MarketBeat recorded 13 mentions for LivaNova and 5 mentions for Glaukos. Glaukos' average media sentiment score of 1.00 beat LivaNova's score of 0.68 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

LivaNova (LIVN) Competitors

$79.58 -1.05 (-1.30%)

As of 11:03 AM Eastern

Compare

LIVN vs. BAX, PEN, SNN, GMED, and GKOS

Should you buy LivaNova stock or one of its competitors? LivaNova's main competitors and comparable companies include Baxter International (BAX), Penumbra (PEN), Smith & Nephew SNATS (SNN), Globus Medical (GMED), and Glaukos (GKOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does LivaNova compare to Baxter International?

LivaNova (NASDAQ:LIVN) and Baxter International (NYSE:BAX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

LivaNova has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

LivaNova has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.16	-$242.47M	$3.38	23.55
Baxter International	$11.47B	1.06	-$957M	-$2.07	N/A

LivaNova has a net margin of 12.82% compared to Baxter International's net margin of -9.27%. Baxter International's return on equity of 16.57% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Baxter International	-9.27%	16.57%	5.24%

LivaNova presently has a consensus target price of $84.13, indicating a potential upside of 5.70%. Baxter International has a consensus target price of $22.45, indicating a potential downside of 4.36%. Given LivaNova's stronger consensus rating and higher possible upside, equities research analysts plainly believe LivaNova is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Baxter International	2 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Baxter International had 8 more articles in the media than LivaNova. MarketBeat recorded 21 mentions for Baxter International and 13 mentions for LivaNova. Baxter International's average media sentiment score of 1.02 beat LivaNova's score of 0.68 indicating that Baxter International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Baxter International	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LivaNova beats Baxter International on 12 of the 16 factors compared between the two stocks.

How does LivaNova compare to Penumbra?

Penumbra (NYSE:PEN) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

LivaNova has a net margin of 12.82% compared to Penumbra's net margin of 10.67%. LivaNova's return on equity of 16.35% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
LivaNova	12.82%	16.35%	7.76%

Penumbra has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.95	$177.69M	$4.07	78.36
LivaNova	$1.39B	3.16	-$242.47M	$3.38	23.55

In the previous week, LivaNova had 6 more articles in the media than Penumbra. MarketBeat recorded 13 mentions for LivaNova and 7 mentions for Penumbra. Penumbra's average media sentiment score of 1.09 beat LivaNova's score of 0.68 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra currently has a consensus target price of $367.07, suggesting a potential upside of 15.10%. LivaNova has a consensus target price of $84.13, suggesting a potential upside of 5.70%. Given Penumbra's higher probable upside, equities analysts clearly believe Penumbra is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Penumbra beats LivaNova on 9 of the 16 factors compared between the two stocks.

How does LivaNova compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Smith & Nephew SNATS has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Smith & Nephew SNATS currently has a consensus target price of $31.91, indicating a potential upside of 13.46%. LivaNova has a consensus target price of $84.13, indicating a potential upside of 5.70%. Given Smith & Nephew SNATS's higher probable upside, equities research analysts clearly believe Smith & Nephew SNATS is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Smith & Nephew SNATS has higher revenue and earnings than LivaNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.30B	1.87	$625M	N/A	N/A
LivaNova	$1.39B	3.16	-$242.47M	$3.38	23.55

LivaNova has a net margin of 12.82% compared to Smith & Nephew SNATS's net margin of 0.00%. LivaNova's return on equity of 16.35% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
LivaNova	12.82%	16.35%	7.76%

In the previous week, LivaNova had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 13 mentions for LivaNova and 9 mentions for Smith & Nephew SNATS. LivaNova's average media sentiment score of 0.68 beat Smith & Nephew SNATS's score of 0.39 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LivaNova beats Smith & Nephew SNATS on 10 of the 14 factors compared between the two stocks.

How does LivaNova compare to Globus Medical?

Globus Medical (NYSE:GMED) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Globus Medical has a net margin of 17.02% compared to LivaNova's net margin of 12.82%. LivaNova's return on equity of 16.35% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
LivaNova	12.82%	16.35%	7.76%

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 18.4% of Globus Medical shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, LivaNova had 8 more articles in the media than Globus Medical. MarketBeat recorded 13 mentions for LivaNova and 5 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.87 beat LivaNova's score of 0.68 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Globus Medical has higher revenue and earnings than LivaNova. Globus Medical is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.40	$537.87M	$3.91	19.05
LivaNova	$1.39B	3.16	-$242.47M	$3.38	23.55

Globus Medical currently has a consensus target price of $101.77, indicating a potential upside of 36.61%. LivaNova has a consensus target price of $84.13, indicating a potential upside of 5.70%. Given Globus Medical's stronger consensus rating and higher possible upside, research analysts plainly believe Globus Medical is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Globus Medical beats LivaNova on 13 of the 17 factors compared between the two stocks.

How does LivaNova compare to Glaukos?

LivaNova (NASDAQ:LIVN) and Glaukos (NYSE:GKOS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

LivaNova presently has a consensus target price of $84.13, suggesting a potential upside of 5.70%. Glaukos has a consensus target price of $178.08, suggesting a potential upside of 4.72%. Given LivaNova's higher possible upside, analysts clearly believe LivaNova is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

LivaNova has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 5.9% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LivaNova has a net margin of 12.82% compared to Glaukos' net margin of -30.68%. LivaNova's return on equity of 16.35% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Glaukos	-30.68%	-6.37%	-4.78%

Glaukos has lower revenue, but higher earnings than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.16	-$242.47M	$3.38	23.55
Glaukos	$507.44M	19.77	-$187.69M	-$3.25	N/A

In the previous week, LivaNova had 8 more articles in the media than Glaukos. MarketBeat recorded 13 mentions for LivaNova and 5 mentions for Glaukos. Glaukos' average media sentiment score of 1.00 beat LivaNova's score of 0.68 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LivaNova beats Glaukos on 9 of the 16 factors compared between the two stocks.

Get LivaNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIVN vs. The Competition

Export

Metric	LivaNova	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.39B	$5.40B	$7.15B	$14.35B
Dividend Yield	N/A	1.80%	2.57%	11.71%
P/E Ratio	23.57	24.79	273.41	25.23
Price / Sales	3.16	82.03	669.66	97.69
Price / Cash	16.17	33.03	28.42	34.96
Price / Book	3.62	5.97	10.32	6.17
Net Income	-$242.47M	$149.33M	$3.48B	$358.05M
7 Day Performance	-1.38%	-1.94%	-2.32%	-1.70%
1 Month Performance	-3.20%	-3.76%	-0.58%	-3.68%
1 Year Performance	43.58%	9.50%	18.51%	5.68%

LivaNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIVN LivaNova	2.3983 of 5 stars	$79.59 -1.3%	$84.13 +5.7%	+43.4%	$4.39B	$1.39B	23.57	3,300	News Coverage Insider Trade
BAX Baxter International	1.4718 of 5 stars	$25.81 -0.1%	$22.45 -13.0%	-0.7%	$13.35B	$11.24B	N/A	37,500	Positive News
PEN Penumbra	3.6733 of 5 stars	$322.28 +0.0%	$367.07 +13.9%	+17.0%	$12.69B	$1.40B	79.18	4,700	Positive News
SNN Smith & Nephew SNATS	2.6092 of 5 stars	$28.91 +0.1%	$30.93 +7.0%	-24.8%	$12.12B	$6.16B	N/A	16,988	Analyst Upgrade Gap Up
GMED Globus Medical	4.3846 of 5 stars	$78.27 0.0%	$101.77 +30.0%	+28.9%	$10.51B	$2.94B	20.02	6,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIVN) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LivaNova (LIVN) Competitors

LIVN vs. BAX, PEN, SNN, GMED, and GKOS

How does LivaNova compare to Baxter International?

Summary

How does LivaNova compare to Penumbra?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Summary

How does LivaNova compare to Globus Medical?

Summary

How does LivaNova compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LivaNova (LIVN) Competitors

LIVN vs. BAX, PEN, SNN, GMED, and GKOS

How does LivaNova compare to Baxter International?

Which has more volatility and risk, LIVN or BAX?

Which has higher earnings & valuation, LIVN or BAX?

Is LIVN or BAX more profitable?

Do analysts recommend LIVN or BAX?

Do institutionals and insiders believe in LIVN or BAX?

Does the media refer more to LIVN or BAX?

Summary

How does LivaNova compare to Penumbra?

Is PEN or LIVN more profitable?

Which has more risk & volatility, PEN or LIVN?

Do institutionals and insiders hold more shares of PEN or LIVN?

Which has better earnings & valuation, PEN or LIVN?

Does the media prefer PEN or LIVN?

Do analysts rate PEN or LIVN?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Which has more risk and volatility, SNN or LIVN?

Do analysts rate SNN or LIVN?

Do institutionals & insiders have more ownership in SNN or LIVN?

Which has preferable valuation and earnings, SNN or LIVN?

Is SNN or LIVN more profitable?

Does the media prefer SNN or LIVN?

Summary

How does LivaNova compare to Globus Medical?

Is GMED or LIVN more profitable?

Do insiders and institutionals believe in GMED or LIVN?

Does the media prefer GMED or LIVN?

Which has more volatility and risk, GMED or LIVN?

Which has better valuation and earnings, GMED or LIVN?

Do analysts prefer GMED or LIVN?

Summary

How does LivaNova compare to Glaukos?

Do analysts prefer LIVN or GKOS?

Which has more volatility & risk, LIVN or GKOS?

Do institutionals and insiders hold more shares of LIVN or GKOS?

Is LIVN or GKOS more profitable?

Which has higher valuation and earnings, LIVN or GKOS?

Does the media prefer LIVN or GKOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools